Year: 2025
Type: article
Study design: Observational Study
Abstract: 3-hydroxi-3 metyl glutaryl coenzyme A reductase inhibitors, also known as statins, are effective in reducing plasmatic cholesterol and thus preventing cardiac, cerebral, and peripheral vascular ischemia. One of the main reasons that limit their use is the potential for muscular disorders, such as the increase of plasmatic CK, myalgia, myositis, and rhabdomyolysis. Myasthenia gravis (MG) is an autoimmune disease characterized by the presence of fluctuating voluntary muscle weakness. It is triggered by antibodies directed against nicotinic acetylcholine receptors (AChR) located at the neuromuscular junction, within the muscle membrane. A number of drugs may either unmask the disease or worsen it when installed. Recent publications have reported on cases of MG who aggravated their condition with the intake of statins. Here, we report on eleven patients who presented symptoms of MG after medication with statins. Six patients received atorvastatin (54.5%), three simvastatin (27.3%), and two rosuvastatin (18.2%)
Institution: Hospital Italiano de Buenos Aires
Language: English
Subfield: Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W106197719